Acrux (FJY) AI Stock Analysis

Acrux

(Frankfurt:FJY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue reboundThe strong 2026 revenue rebound shows that Acrux retained the ability to generate materially higher sales after a difficult period. If maintained, renewed top-line traction can support operating leverage, improve funding capacity, and strengthen the commercial base for future growth.

Negative Factors

Persistent lossesPersistent net, EBIT, and EBITDA losses show that the current business has not yet demonstrated a sustainable profit engine. Ongoing operating losses can consume resources, limit reinvestment, and keep Acrux dependent on improved revenue or additional financing.

Acrux (FJY) vs. iShares MSCI Germany ETF (EWG)

Not enough price history over this period.

Market Cap: EUR 40.14K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -7.1
Beta (1Y): 1.44
Revenue Growth: 292.45%
EPS Growth: 91.51%
Country: Germany
Employees: 43
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Acrux Business Overview & Revenue Model

Company Description

Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international...

Acrux Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:FJY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:CUV	73Outperform	AUD 364.52M	10.62	13.00%	0.69%	-1.05%	-6.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:CMB	51Neutral	AUD 11.77M	-1.59	-247.44%	―	-4.24%	33.39%
AU:BOT	41Neutral	AUD 27.63M	-0.31	-118.74%	―	499.47%	31.20%
AU:SPL	40Underperform	AUD 217.31M	-26.32	-42.35%	―	145.32%	25.75%
AU:TRP	32Underperform	AUD 5.06M	-1.07	-52.04%	―	32.22%	-26.53%

* Healthcare Sector Average

Performance Comparison

DE:FJY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:FJY	Acrux Limited	―	―	―
AU:CUV	Clinuvel Pharmaceuticals Limited	7.22	-4.02	-35.78%
AU:SPL	Starpharma Holdings Limited	0.45	0.11	32.35%
AU:TRP	Tissue Repair Ltd	0.10	-0.24	-71.21%
AU:CMB	Regeneus Ltd.	0.40	-0.09	-19.19%
AU:BOT	Botanix Pharmaceuticals Limited	0.01	-0.12	-92.31%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Acrux AI Stock Analysis